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of the Notch signaling pathway could induce S-phase complex signals results in the formation of regularly
entry, resulting in disc overgrowth. Notch acts in part by spaced groups of cells across the length of the furrow
inhibiting the Drosophila retinoblastoma homolog Rbf, that are committed to differentiate into neurons. That
which normally functions to inhibit the S-phase-specific cell-cycle entry behind the morphogenetic furrow de-
E2F transcription factor. Notch is also required for ex- pends on these same regulatory signals ensures that
pression of Cyclin A; in addition, Notch may regulate a precursor cells will be generated at the right time and
third, unknown factor to drive S-phase entry because place and in the right numbers to pattern the adult eye.
coexpression of both E2F and Cyclin A did not rescue Although it is likely that the highly structured nature of
S phase in Notch mutant clones (Baonza and Freeman, the Drosophila compound eye requires an unusually
2005). Once cells transit through S phase into G2, they stringent control, it is likely that proliferation and
arrest until a further signal from differentiating neurons, patterning will be linked by common regulatory signals
dependent on the epidermal growth factor receptor, in other organisms as well.
drives entry into mitosis (Baker and Yu, 2001).
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diate cell-cycle synchronization and arrest within the Center for Cancer Research
morphogenetic furrow? One likely target is String, the National Cancer Institute
Drosophila homolog of the mitotic inducer Cdc25. National Institutes of Health
String expression ahead of the furrow is required to 9000 Rockville Pike
drive cells through mitosis and into G1 (Heberlein et Bethesda, Maryland 20892
al., 1995; Mozer and Easwarachandran, 1999). Another
candidate is Roughex, a gene required to inhibit Cyclin
A-dependent kinase activity in the morphogenetic fur- Selected Reading
row. In the absence of Roughex, all cells in the furrow
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expression is required for Notch activity in regulating Finley, R.L., Brent, R., Lehner, C.F., and Zipursky, S.L. (1997). Genes
Dev. 11, 1289–1298.S-phase entry behind the morphogenetic furrow








gProinflammatory cytokine TNF triggers cell death by
finducing reactive oxygen species (ROS). These then
ainflict cytotoxicity through downstream activation of
ethe JNK MAPK cascade. Yet the mechanisms by which
oROS trigger JNK signaling have remained elusive. In
aa recent issue of Cell, Kamata et al. now provide one
(such mechanism.
t
It might be surprising to know that we are not the firstiving beings to have caused a profound change in the
omposition of Earth’s atmosphere. Over 2.2 billion
ears ago, oxygen became abundant as a result of
early” life, causing radical changes to the ecosystem
ith consequences potentially far more harmful than
oday’s “green-house effect.” This accumulation of oxy-
en caused extinction of most existing life forms, de-
enseless against oxidation-mediated toxicity. Eventu-
lly new life forms emerged and flourished in the new
nvironment. This aerobic life possessed effective anti-
xidant mechanisms and even began exploiting oxygen
nd its derivates—so-called reactive oxygen species
ROS)—for production of energy and signal transduc-
ion.
One pathway that harnessed the potent reactivity of
Preview
453ROS as second messengers for signal transduction is
the TNF-R1 pathway—critical for controlling inflamma-
tion, immunity, cell death, and proliferation (Wajant et
al., 2003). This pathway also plays a central role in can-
cer and chronic inflammation and has attracted major
biomedical interest for the last 100 years. Like other so-
called “death receptors,” TNF-R1 is hardwired into the
machinery of programmed cell death (PCD) (Wajant et
al., 2003). Yet, despite this potential for killing cells, en-
gagement of TNF-R1 by its ligand, TNFα, does not usu-
ally cause death, owed to potent activation of NF-κB
transcription factors (Wajant et al., 2003). Several
laboratories have now shown that this protective activ-
ity of NF-κB against TNFα-induced killing involves sup-
pressing accumulation of ROS and sustained activation
of the JNK MAPK cascade (De Smaele et al., 2001; Tang
et al., 2001; Sakon et al., 2003; Pham et al., 2004) (Figure
1). These antioxidant and prosurvival actions of NF-κB
are mediated in part by upregulation of the iron binding
protein, Ferritin Heavy Chain, and the ROS scavenger,
Mn2+ Superoxide Dismutase (Mn-SOD) (Pham et al.,
2004; Kamata et al., 2005). ROS and JNK have both
been found to play obligatory roles in TNF-R1-induced
killing, and indeed, their activities appear to be linked
because ROS-triggered cytotoxicity depends on down-Figure 1. Death and Survival Signaling Pathways Downstream of
TNF-R1
Ligand engagement of TNF-R1 initiates accumulation of ROS,
which promotes cell death through activation of the JNK MAPK
cascade. This occurs via at least two mechanisms: inactivation of
MKPs and activation of ASK1. TNFα-induced sustained activation
of JNK signaling can then mediate both the apoptotic and caspase-
independent necrotic pathways of PCD. Death signaling triggered
by ROS-mediated activation of JNK is antagonized by NF-κB,
which upregulates expression of protective genes such as FHC and
Mn-SOD (suppressing ROS), and Gadd45β, A20, and XIAP (block-
ing the JNK pathway directly).stream activation of the JNK pathway (Pham et al.,
2004; Kamata et al., 2005). The precise mechanism(s)
by which ROS promotes activation of JNK, however,
has remained elusive.
A new study by Karin and colleagues (Kamata et al.,
2005) now provides one such mechanism. The study
identifies JNK phosphatases of the MKP group as criti-
cal molecular targets of ROS in TNFα-induced PCD.
ROS-mediated inactivation of MKPs—key effectors for
extinguishing MAPK activity—seems to involve oxida-
tion of a critical cysteine residue in their catalytic do-
main. ROS-dependent loss of MKP function then leads
to persistent activation of JNK by TNFα, triggering
mitochondrial release of cytochrome c and, ultimately,
PCD via necrosis and apoptosis (Figure 1).
The study provides important new insights into the
basis of ROS-mediated activation of proapoptotic JNK
signaling and opens new avenues for investigation (see
below). Some cautionary notes, however, seem appro-
priate. First, the proposed model is supported mainly
by data obtained with pharmacological and dominant-
negative inhibitors and, so, requires genetic validation
with knockout systems. Additionally, it is worth noting
that inactivation of MKPs is unlikely to be the sole
mechanism by which ROS promote JNK signaling. Pre-
vious knockout studies suggest that ROS also activate
ASK1/MEKK5, a MAPKKK needed for sustained JNK
induction and PCD downstream of TNF-R1 (Matsuzawa
and Ichijo, 2005). Therefore, ROS might influence JNK
activation by controlling both activating kinases and
inhibitory phosphatases (Figure 1), the relative impor-
tance of which may depend on biological context.
Some controversial issues also await resolution. One
pertains to whether NF-κB also blunts activity of p38—
another MAPK attenuated by MKPs—as suggested by
this study. Other groups have reported, in fact, that the
inhibitory action of NF-κB is specific to the JNK MAPK
cascade (Tang et al., 2001; Reuther-Madrid et al., 2002).
There is also discrepancy in published studies regard-
ing the effects of NF-κB on JNK activation by IL-1β-R
(Tang et al., 2001; Sakon et al., 2003; Kamata et al.,
2005), which does not promote accumulation of ROS.
Resolutions to these issues will help establish which
downstream targets of NF-κB are most relevant to NF-
κB-mediated cytoprotection in specific contexts.
Notably, the study highlights important challenges for
the future. Foremost, the primary source(s) of signal-
transducing ROS downstream of TNF-R1 still needs to
be identified. It is often assumed that TNFα-induced
ROS originate in mitochondria. However, prior studies
(including the current one by Kamata et al.) have mea-
sured ROS production at relatively late times (i.e.,
hours), and so, these measurements are likely compli-
cated by the oxidative burst that follows mitochondrial
outer membrane depolarization, a sign that cells may
have already committed to die. Thus, whether mito-
chondrial ROS are a cause or secondary consequence
of cell death remains unclear. Indeed, the observations
that ROS are not induced by IL-1β (Kamata et al., 2005)
and that their induction by TNFα is blocked by ablation
of JNK1/2 (Ventura et al., 2004) could be simply ex-
plained by lack of cell death. The notion of a primarily
mitochondrial origin of TNF-R1-stimulated ROS is also
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454challenged by the weak protective activity of mito- h
ichondrial Mn-SOD (Sakon et al., 2003; Pham et al.,
2004). Putative extramitochondrial sources of TNF-R1- I
ainduced ROS have in fact been identified. Ultimately,
identifying the origin of ROS will require employing ge- p
anetic tools and more sophisticated methods for detect-
ing early ROS and discriminating individual species. t
Finally, there is evidence to suggest that the coupling
of ROS and JNK signaling downstream of TNF-Rs is C
Fbidirectional. It has been proposed that in the TNF-R1-
triggered pathway for necrosis, ROS lie downstream T
T(rather than upstream) of JNK (Ventura et al., 2004).
Thus, the molecular ordering of JNK and ROS signaling 9
Cmight differ depending upon the type of PCD response
initiated by TNF-Rs. Indeed, this represents another im-
portant issue for future investigation.
SThe actual outcome of TNF-R stimulation depends
upon the biological context and tissue in which this
D
stimulation occurs. Undoubtedly, major future chal- J
lenges include determining the precise mechanisms by K
which ROS promote JNK activation and PCD and as- M
sessing which target genes are most relevant to the M
antioxidant activity of NF-κB in specific tissues and 4
contexts. The use of conditional knockout models will P
Kbe key for addressing these issues. Because the NF-
(κB-mediated attenuation of TNFα-induced killing plays
Ra crucial role in human diseases, gaining understanding
Dof how ROS trigger PCD and how NF-κB promotes sur-
Cvival might enable development of entirely novel ap-
Sproaches to treatment of these diseases, one that is
Y
effective and yet lacks the serious immunosuppressive (
side effects of general NF-κB blockers.
T
The study by Kamata et al. provides an exemplary a
illustration of this concept. It shows that in the liver, V
ROS-mediated activation of JNK signaling plays a se- R
lective role in TNF-R-mediated hepatic injury induced W
Dby concanavalin-A, but not in regeneration postpartialepatectomy, albeit both processes are governed by
ntegration of activities of TNF-Rs, JNK, and NF-κB.
dentifying the mechanisms responsible for ROS-medi-
ted JNK induction and NF-κB-dependent protection in
atho-physiological contexts such as these represents
major challenge yet holds great promise of yielding
he key for a new type of approach to therapy.
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